Soligenix Announces Formation of Beh ƒ §et's Disease Medical Advisory Board
Stockwatch,
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J., Feb.
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J., Feb.
Phase 2a clinical study of SGX945 in Behçet’s Disease initiating in 2024 PRINCETON, N.J., Feb.
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J., Feb.
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board PR Newswire PRINCETON, N.J., Feb.